产品
编 号：F360592
分子式：C21H28N2O8S2
分子量：500.59
分子式：C21H28N2O8S2
分子量：500.59
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 447410-57-3
产品详情
生物活性：
SB756050 is a selective TGR5 agonist. SB756050 has the potential for type 2 diabetes treatment.
体内研究：
SB756050 is well‐tolerated; it is readily absorbed, exhibited nonlinear pharmacokinetics with a less than dose‐proportional increase in plasma exposure above 100 mg, and demonstrates no significant changes in exposure when co‐administered with sitagliptin. SB756050 demonstrates highly variable pharmacodynamic effects both within dose groups and between doses, with increases in glucose seen at the two lowest doses and no reduction in glucose seen at the two highest doses. The glucose effects of SB756050 sitagliptin are comparable to those of sitagliptin alone, even though gut hormone plasma profiles are different.
体外研究：
TGR5 is a bile acid receptor and a potential target for the treatment of type 2 diabetes (T2D).
SB756050 is a selective TGR5 agonist. SB756050 has the potential for type 2 diabetes treatment.
体内研究：
SB756050 is well‐tolerated; it is readily absorbed, exhibited nonlinear pharmacokinetics with a less than dose‐proportional increase in plasma exposure above 100 mg, and demonstrates no significant changes in exposure when co‐administered with sitagliptin. SB756050 demonstrates highly variable pharmacodynamic effects both within dose groups and between doses, with increases in glucose seen at the two lowest doses and no reduction in glucose seen at the two highest doses. The glucose effects of SB756050 sitagliptin are comparable to those of sitagliptin alone, even though gut hormone plasma profiles are different.
体外研究：
TGR5 is a bile acid receptor and a potential target for the treatment of type 2 diabetes (T2D).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备